Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pemetrexed plus Irinotecan in 2nd-Line Metastatic Colorectal Cancer
NCT00191984Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jun 2004
- Primary completion
- Feb 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pemetrexed in metastatic colorectal cancer (mCRC), sponsored by Eli Lilly and Company. Primary endpoint: Best Overall Tumor Response up to 2 years. Started Jun 2004; status: completed.
02
Drugs
pemetrexed
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT00191984.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00191984.